Schizophrenia Termination Of Pharmacotherapy-STOP-trial.
Suspended
- Conditions
- Schizophrenic disorders:SchizophreniaSchizophreniform disorderSchizoaffective disorder
- Registration Number
- NL-OMON26866
- Lead Sponsor
- Divisie Hersenen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Written informed consent obtained after oral and written explanation to the patient and its doctor;
Exclusion Criteria
1. Judgement of the treating psychiatrist of the patient;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse, operationalized as follows:<br /><br>The reappearance of psychotic symptoms:<br /><br>1. As measured by an increase in the total score on the PANSS with at least 20%, and the score of 1 of the following PANSS items being more than 3: Delusions (P1), Conceptual disorganisation (P2), Hallucinations (P3) and Suspicion (P6); OR<br><br />2. As expressed by the necessity (and actual fact) of an admittance for psychiatric reasons.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antipsychotic discontinuation in schizophrenia?
How does antipsychotic withdrawal compare to standard-of-care maintenance in preventing neurological impairment?
Which biomarkers predict response to antipsychotic discontinuation in schizoaffective disorder?
What adverse events are associated with stopping antipsychotics in schizophrenia patients?
Are there alternative compounds or combination therapies to antipsychotics for managing schizophrenic disorders?